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OBJECTIVE—GPR40 is a G protein–coupled receptor regulat-
ing free fatty acid–induced insulin secretion. We generated
transgenic mice overexpressing the hGPR40 gene under control
of the mouse insulin II promoter and used them to examine the
role of GPR40 in the regulation of insulin secretion and glucose
homeostasis.
RESEARCH DESIGN AND METHODS—Normal (C57BL/6J)
and diabetic (KK) mice overexpressing the hGPR40 gene under
control of the insulin II promoter were generated, and their
glucose metabolism and islet function were analyzed.
RESULTS—In comparison with nontransgenic littermates,
hGPR40 transgenic mice exhibited improved oral glucose toler-
ance with an increase in insulin secretion. Although islet mor-
phologic analysis showed no obvious differences between
hGPR40 transgenic and nontransgenic mice, isolated islets from
hGPR40 transgenic mice had enhanced insulin secretion in
response to high glucose (16 mmol/l) compared with those from
nontransgenic mice, and they both had similar low glucose (3
mmol/l)-stimulated insulin secretion. In addition, hGPR40 trans-
genic islets signiﬁcantly increased insulin secretion against a
naturally occurring agonist palmitate in the presence of 11
mmol/l glucose. hGPR40 transgenic mice were also found to be
resistant to high-fat diet–induced glucose intolerance, and
hGPR40 transgenic mice harboring KK background showed
augmented insulin secretion and improved oral glucose tolerance
compared with nontransgenic littermates.
CONCLUSIONS—Our results suggest that GPR40 may have a
role in regulating glucose-stimulated insulin secretion and
plasma glucose levels in vivo and that pharmacological activation
of GPR40 may provide a novel insulin secretagogue beneﬁcial for
the treatment of type 2 diabetes. Diabetes 58:1067–1076, 2009
F
ree fatty acids (FFAs) serve not only as nutrients
but also as cell signaling mediators (1), and they
are implicated in several metabolic disorders,
including diabetes. Elevated circulating FFAs
cause insulin resistance and impair glucose metabolism in
liver, muscle, adipose tissue, and pancreatic -cells (2). In
pancreatic -cells, prolonged exposure to elevated levels
of fatty acids together with high levels of glucose impairs
-cell function (3,4) and induces cell death (5). In contrast
to the toxic effects that accompany chronic exposure, in
acute treatment FFAs play an essential role to amplify
glucose-stimulated insulin secretion (6,7).
GPR40 was identiﬁed as a receptor for medium- and
long-chain FFAs and is preferentially expressed at high
levels in rodent primary -cells, -cell lines (8–11), and
human islets (12,13). Several reports have shown that
GPR40 is mainly coupled with Gq/G11, which activates
phosholipase C (PLC), resulting in the formation of inosi-
tol 1,4,5-triphosphate and induction of calcium release
from endoplasmic reticulum (11,14–16). In fact, FFAs
increase intracellular calcium concentration via GPR40
and lead to glucose-dependent augmentation of insulin
secretion (8–11,15,17).
Although several studies have shown the important role
of GPR40 in FFA-induced insulin secretion, the involve-
ment of GPR40 in FFA-induced lipotoxicity in -cells
remains controversial. Steneberg et al. (18) reported that
overexpression of GPR40 in -cells under the control of
insulin promoter factor 1 (IPF-1)/pancreatic and duodenal
homeobox factor 1 (PDX-1) promoter lead to -cell dys-
function, hypoinsulinemia, and diabetes. In contrast, stud-
ies of GPR40 knockout mice showed that GPR40 did not
play a role in the mechanism by which chronic treatment
with fatty acids impaired insulin secretion (19,20). Fur-
thermore, both acute and chronic treatment by small-
molecule agonists of GPR40 caused enhancement of
glucose-stimulated insulin secretion and improved glucose
tolerance (20–22). Together, these reports suggested that
a GPR40 agonist might not be harmful to -cells but, in
fact, may prove beneﬁcial for the treatment of type 2
diabetes.
To clarify the function of GPR40 in pancreatic -cells
more extensively, we generated transgenic mice overex-
pressing the human GPR40 (hGPR40) gene under control
of the insulin II promoter and examined the role of GPR40
in the regulation of insulin secretion and glucose ho-
meostasis. We found that hGPR40 transgenic mice dis-
played improved glucose tolerance with augmented
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conditions. Moreover, even when insulin resistance was
reinforced in diabetic KK mice, overexpression of hGPR40
in this background also improved glucose tolerance with
increasing insulin secretion. Thus, our ﬁndings indicated
that GPR40 has a role in regulating glucose-stimulated
insulin secretion and plasma glucose levels in vivo, and
they supported the concept that GPR40 agonists might be
effective insulin secretagogues for the treatment of type 2
diabetes.
RESEARCH DESIGN AND METHODS
Generation of hGPR40 transgenic mice. The transgene consisted of 0.7
kbp of mouse insulin II gene promoter, followed by 2.2 kbp of the hGPR40
gene, including the 3 noncoding region (8), and the complete 2.9-kbp
fragment was puriﬁed and microinjected into the fertilized eggs of C57BL/6J
mice (CLEA Japan, Tokyo) (23). The transgenic mice obtained were main-
tained by crossing with C57BL/6J mice, and the transgenic founder mice were
identiﬁed by PCR analyses of tail DNA using the hGPR40 gene–speciﬁc
primers 5-GGAGTGTGGTGCTTAATCCGCTGGT-3 and 5-AGACTGCCTC-
CTCCTTCCCGTAAGTACAA-3. When examining the hGPR40 transgenic mice
harboring KK hybrid background, hGPR40 transgenic mice were crossed with
mice harboring a KK background, and the mice obtained contained almost
50% KK background (hGPR40 transgenic  KK). The transgene was identiﬁed
by PCR analyses of tail DNA using the hGPR40-speciﬁc primers described
above. Age- and sex-matched littermates were used as control mice through-
out the study, and all experiments were conducted using male mice, unless
otherwise stated. The mice were fed with a regular diet containing 11.5 kcal%
fat (CE-2; CLEA Japan) and were housed in colony cages and maintained on
a 12-h light/dark cycle with free access to water and food. When examining the
effects of high-fat–diet feeding, mice were fed with a high-fat diet containing
60 kcal% fat (D12492; Research Diets, New Brunswick, NJ) from 8 weeks of
age. Plasma glucose levels were automatically analyzed by Dri-Chem (FujiF-
ilm Medical, Tokyo), and plasma nonesteriﬁed fatty acids (NEFAs) were
determined using a Wako test (Wako Pure Chemical Industries, Osaka, Japan).
Plasma insulin levels were measured by enzyme-linked immunosorbent assay
(Morinaga Institute of Biological Science, Tokyo). All procedures were
conducted according to the experimental animal care use committee of
Takeda Pharmaceutical.
Oral glucose tolerance test. Mice were orally administered glucose at a
dose of 1 g/kg body wt for C57BL/6J mice or 2 g/kg body wt for KK hybrid mice
after an overnight fast. In the case of C57BL/6J mice, blood samples were
obtained at time 0 (just before glucose load), and 7.5, 15, 30, 60, and 120 min
after glucose administration, followed by plasma preparation by centrifuga-
tion. For KK hybrid mice, blood samples were collected at 10 min instead of
7.5 and 15 min. Plasma glucose and insulin levels were measured as described
above.
Insulin tolerance test. Insulin was injected intraperitoneally at 0.5 units/kg
body wt (Novo Nordisk, Bagsværd, Denmark) after an overnight fast. Blood
samples were obtained at time 0 (just before insulin injection) and 30, 60, and
120 min after insulin injection, followed by plasma preparation by centrifuga-
tion. Plasma glucose level was measured as described above.
Preparation of islets. Islets were isolated from pancreata by collagenase
digestion (24). The solution of 183 units  mg
1  kg
1 collagenase (Wako Pure
Chemical Industries) dissolved in Hanks’ balanced salt solution (Invitrogen,
Carlsbad, CA) containing 10 g/ml DNase I (Roche Diagnostics, Indianapolis,
IN) and 0.2% BSA (Wako Pure Chemical Industries) was injected into the
common bile duct. The pancreas was removed and incubated at 37°C for 20
min and washed three times with Hanks’ balanced salt solution, and islets
were hand-collected under a microscope. Freshly puriﬁed islets were used for
gene expression experiments. For insulin secretion experiments, puriﬁed
islets were used after overnight culture in RPMI 1640 medium containing 5.5
mmol/l glucose and 10% fetal bovine serum in a humidiﬁed atmosphere
containing 5% CO2/95% air at 37°C.
RNA extraction and gene expression analysis. Total RNA was extracted
from the isolated islets, liver, subcutaneous adipose tissue, muscle, brain, and
kidney using an RNeasy Mini kit (Qiagen, Tokyo), and reverse transcription
was performed with random hexamer and reverse transcriptase (GE Health-
care, Chalfont St. Giles, U.K.). Quantitative real-time PCR analyses were
performed using a Prism 7700 sequence detector (Applied Biosystems, Foster
City, CA), following the manufacture’s instructions. The primers were as
follows: 5-GCCCGCTTCAGCCTCTCT-3 and 5-GAGGCAGCCCACG-
TAGCA-3 with 5-FAM-TCTGCCCTTGGCCATCACAGCCT-TAMRA-3 Taq-
Man probe for the hGPR40 gene, 5-GGGCCTCTGGAAAGGGACT-3 and
5-ACCAGCTCAGCACAGTTGACA-3 with 5-FAM-TCCCAATGTTGCCCGTA-
ATGCCA-TAMRA-3 TaqMan probe for the mouse uncoupling protein 2
(UCP2) gene, and 5-CGTGAAAAGATGACCCAGATCA-3 and 5-CACAGCCT-
GGATGGCTACGT-3 with 5-FAM-TGAGACCTTCAACACCCCAGCCATG-
TAMRA-3 TaqMan probe for the mouse actin gene. The mouse GPR40, insulin
II, GLUT2, and glucokinase genes were quantiﬁed by gene expression assays
(Mm00809442_m1, Mm00731595_gH, Mm00446224_m1, and Mm00439129_m1,
respectively; Applied Biosystems).
Insulin secretion assay. A group of ﬁve islets was preincubated in Krebs-
Ringer bicarbonate buffer (KRBH) containing 0.2% BSA and 1 mmol/l glucose
for 30 min at 37°C and then incubated for another1hi nKRBH containing
glucose. When examining the effect of the fatty acids, sodium palmitate (Chem
Service, West Chester, PA) was conjugated with FFA-free BSA (Sigma Aldrich,
St. Louis, MO) at ﬁnal palmitate and BSA concentrations of 1 mmol/l and 0.2%,
respectively. The conjugated palmitate was added to KRBH containing 11
mmol/l glucose and incubated for 1 h. At the end of the incubation period, the
amount of insulin in the culture supernatant was determined with enzyme-
linked immunosorbent assay as described above. Residual islets were soni-
cated and used to determine the DNA content (Quant-iT Picogreen dsDNA
assay kit; Invitrogen).
Immunohistochemistry of pancreas. Formalin-ﬁxed, parafﬁn-embedded
tissue sections (thickness 4 m) of pancreas were immunostained using an
avidin-biotin detection system (Ventana Medical Systems, Tucson, AZ) and an
M.O.M. immunodetection kit (Vector Laboratories, Burlingame, CA), accord-
ing to the manufacturer’s instructions. Anti-insulin antibody (1:200; MP
Biomedicals, Morgan Irvine, CA), anti-glucagon antibody (1:2; Zymed, South
San Francisco, CA), anti-GLUT2 antibody (1:200; Chemicon International,
Temecula, CA), and anti-proinsulin antibody (ready-to-use; Lab Vision, Fre-
mont, CA) were used as primary antibodies. When examining the -cell area,
the area of the islets was traced manually and analyzed with Win Roof
software (Mitani, Fukui, Japan). We analyzed 20 islets per pancreas for the
average calculation.
Statistical analysis. Statistical analysis was performed using SAS system
version 8.2 (SAS Institute, Cary, NC). All values were expressed as the
means  SE. Statistical signiﬁcance between groups was analyzed by Stu-
dent’s t test.
RESULTS
Improved glucose tolerance in hGPR40 transgenic
mice harboring normal background. To investigate the
role of the GPR40 gene in pancreatic -cells, we generated
mice overexpressing hGPR40 cDNA under control of the
mouse insulin II promoter (Fig. 1A). Two transgene-
expressing lines, named hGPR40 transgenic 47M and 23F,
were established by microinjection of the construct into
C57BL/6J oocytes. High expression levels of the hGPR40
gene were conﬁrmed in isolated islets from both trans-
genic lines (male) at 9 weeks of age (Fig. 1B). The
expression levels of hGPR40 mRNA were 10 times
higher than those of the endogenous mouse GPR40 gene in
both of the two lines. The 47M line showed 2.8 times
higher expression levels of the hGPR40 mRNA in islets
than the 23F line. Expression of the hGPR40 gene was
extremely low in other tissues; slight expression was
found in kidney in the 47M line, but the expression level
in kidney in the 23F line was extremely low. These
transgenic lines appeared generally normal, reproduced
successfully, and showed Mendelian inheritance
characteristics.
Neither hGPR40 transgenic line (47M and 23F) showed
signiﬁcant differences in body weight, plasma glucose,
plasma insulin, or NEFA levels compared with nontrans-
genic mice in the fed state on a regular diet (Table 1).
However, fasting plasma glucose levels were lower in
hGPR40 transgenic than in nontransgenic mice. To assess
the glucose homeostasis in these mice more precisely, oral
glucose tolerance and insulin tolerance tests were per-
formed, and the area under the curve (AUC) for glucose
and insulin was calculated. AUC0–120 min of plasma glucose
after glucose load in both lines of hGPR40 transgenic mice
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(Fig. 2A, B, and E). In parallel with improvement of
glucose tolerance, insulin responses to glucose at the early
phase were higher in both hGPR40 transgenic lines than in
nontransgenic mice (Fig. 2C and D), and AUC0–30 min of
plasma insulin was signiﬁcantly increased in both lines of
hGPR40 transgenic mice compared with nontransgenic
mice (Fig. 2F). Whole-body insulin sensitivity was as-
sessed by the insulin tolerance test, and no apparent
differences were observed between hGPR40 transgenic
and nontransgenic mice (Fig. 2G and H).
Islet structure and -cell function in vitro. We next
examined whether hGPR40 overexpression affects islet
structure. At 16 weeks of age, immunohistochemical anal-
ysis of pancreas sections with antibodies against insulin,
glucagon, GLUT2, and proinsulin showed no apparent
differences between hGPR40 transgenic (47M and 23F)
and nontransgenic mice (Fig. 3A). -Cell areas of 47M and
23F lines were almost the same as those of nontransgenic
mice (Fig. 3B). To further examine the effects of the
hGPR40 overexpression on islet function, isolated islets
from hGPR40 transgenic (47M and 23F) mice and non-
transgenic mice at 9 weeks of age were stimulated with
glucose or glucose plus palmitate in vitro, and secreted
insulin was measured. Basal insulin secretion at low
glucose concentration (3 mmol/l) was similar between
hGPR40 transgenic and nontransgenic islets, but isolated
islets from hGPR40 transgenic mice had enhanced insulin
secretion in response to high glucose (16 mmol/l) com-
pared with islets from nontransgenic mice (Fig. 3C).
Similar results were obtained when using islets isolated
from the 23F line (Fig. 3D). Stimulation with palmitate,
one of the naturally occurring agonists of GPR40, signiﬁ-
cantly increased insulin secretion in islets of hGPR40
transgenic mice compared with those of nontransgenic
mice at 11 mmol/l glucose, indicating that the expressed
hGPR40 might be functional in -cells of hGPR40 trans-
genic mice (Fig. 3E). These results suggest that the quan-
tity of insulin secretion was more enhanced than that of
insulin synthesis in hGPR40 transgenic mice islets.
Effects of high-fat–diet feeding on glucose homeosta-
sis in hGPR40 transgenic mice. Because GPR40 is the
receptor for medium- and long-chain FFAs (8–10), and a
A
B
FIG. 1. Generation and characterization of hGPR40 transgenic mice. A:
A DNA construct for microinjection to generate transgenic mice for the
mouse insulin II promoter and hGPR40 gene. The box denotes the
coding region of hGPR40 cDNA. B: Human and mouse GPR40 mRNA
levels from hGPR40 transgenic (47M, 23F, n  3) and nontransgenic
mice (n  3) by quantitative real-time PCR analyses. mRNA levels of
actin were used as an internal control. A, subcutaneous adipose tissue;
B, brain; Is, islet; K, kidney; L, liver; M, muscle; NonTg, nontransgenic;
Tg, transgenic.
TABLE 1
Metabolic parameters in hGPR40 transgenic (47M and 23F) mice fed a regular diet or a high-fat diet
Body weight
(g)
Plasma glucose
(mg/dl)
Plasma insulin
(ng/ml)
Plasma NEFA
(mEq/l)
Regular diet
Fed
Nontransgenic 28.8  0.4 170.0  4.1 1.54  0.30 0.33  0.08
Transgenic(47M) 27.5  0.6 153.6  6.2 1.61  0.43 0.24  0.06
Nontransgenic 28.7  0.4 187.6  9.8 1.43  0.38 0.37  0.08
Transgenic (23F) 28.1  0.3 161.4  8.1 1.46  0.38 0.41  0.06
Fasted
Nontransgenic 24.3  0.4 106.0  4.8 0.19  0.04 1.35  0.06
Transgenic (47M) 22.9  0.6 84.5  4.4* 0.23  0.05 1.00  0.07
Nontransgenic 24.0  0.3 117.7  5.0 0.21  0.03 1.07  0.07
Transgenic (23F) 23.6  0.3 89.9  5.2* 0.24  0.05 0.98  0.07
High-fat diet
Fed
Nontransgenic 49.9  0.7 215.6  8.1 18.87  3.52 0.52  0.04
Transgenic (47M) 49.6  1.0 212.8  9.9 16.17  2.95 0.49  0.03
Fasted
Nontransgenic 46.0  0.6 173.8  5.6 2.88  0.31 0.80  0.04
Transgenic (47M) 45.4  0.9 133.3  4.5* 3.07  0.39 0.80  0.04
All parameters were measured in the fed and fasted states at 16 weeks of age on a regular diet. The hGPR40 transgenic (47M) and
nontransgenic mice were fed a high-fat diet containing 60 kcal% fat for 12 weeks. All parameters were measured in the fed and fasted state
at 20 weeks of age. All values are the means  SE, n 	 7–10 per genotype. *P  0.01 vs. nontransgenic mice by Student’s t test.
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FFA-induced lipotoxicity in -cells (18), we next explored
the function of GPR40 in vivo under high-fat–diet condi-
tions. hGPR40 transgenic mice (47M) were exposed to
high-fat diet (containing 60 kcal% fat) for 9–12 weeks from
8 weeks of age. When nontransgenic mice were exposed to
high-fat diet, body weight, plasma glucose, insulin, and
NEFA levels in the fed state were increased compared
with regular diet (Table 1). There were no obvious differ-
ences in body weight and plasma parameters in the fed
state between hGPR40 transgenic and nontransgenic mice,
but fasting plasma glucose levels were signiﬁcantly re-
duced in hGPR40 transgenic mice in high-fat–diet condi-
tions compared with those observed in regular diet
conditions (Table 1). Oral glucose tolerance testing
showed improved glucose tolerance (Fig. 4A and C) and
augmented insulin secretion in response to glucose (Fig.
4B and D) in hGPR40 transgenic mice compared with
nontransgenic mice. No apparent difference in insulin
sensitivity or in epididymal adipose tissue weight was
observed between hGPR40 transgenic and nontransgenic
mice (Fig. 4E and F). These results indicate that improved
glucose tolerance with increased insulin secretion in
hGPR40 transgenic mice was maintained under conditions
of high-fat–diet–induced insulin resistance.
Improved glucose tolerance in hGPR40 transgenic
mice harboring a diabetic genetic background. The
effects of overexpression of GPR40 in pancreatic -cells
were examined in genetically diabetic mice. Mice harbor-
ing KK background and, exhibiting obesity, glucose intol-
erance, and insulin resistance (25) were selected as mates,
and male hGPR40 transgenic (47M) and nontransgenic
mice were crossed to female mice harboring KK back-
ground. Although the mice obtained had a hybrid genetic
background harboring 
50% each of KK and C57BL/6J, the
nontransgenic mice obtained (nontransgenic  KK mice)
showed heavier body weight and higher plasma insulin
levels than nontransgenic C57BL/6J mice at 16 weeks of
age fed with regular chow (body weight 28.8  0.4 vs.
38.9  0.57 g, plasma insulin 1.54  0.30 vs. 5.79  1.83
ng/ml for nontransgenic C57BL/6J vs. nontransgenic  KK,
respectively; n 	 7–10). hGPR40 gene expression level in
islets of hGPR40 transgenic  KK mice was 10 times
higher than that of the mouse gene (Fig. 5A). The hGPR40
FIG. 2. Improved glucose tolerance in hGPR40 transgenic mice harboring C57BL/6J background. Oral glucose tolerance testing was conducted in
nontransgenic and hGPR40 transgenic on a regular diet. Glucose was administered orally at 1 g/kg body wt. Panels show plasma glucose and
plasma insulin in the 47M line at 16 weeks of age (n  8) (A and C) and in the 23F line at 15 weeks of age (n  10) (B and D). Data in panel E
represent the AUC0–120 min of the plasma glucose shown in panels A and B, and data in panel F represent the AUC0–30 min of the plasma insulin
shown in panels C and D. G and H: Insulin tolerance test for nontransgenic and hGPR40 transgenic mice. Insulin was injected intraperitoneally
at 0.5 units/kg. Panels show plasma glucose on regular diet at 14–15 weeks of 47M (n  13–15) (G) and 23F (n  5–7) (H), respectively. All values
are the means  SE. **P < 0.01, *P < 0.05 vs. nontransgenic mice by Student’s t test. NonTg, nontransgenic; Tg, transgenic.
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in body weight, plasma glucose, and insulin levels com-
pared with nontransgenic  KK mice at 10 weeks of age
(Table 2). Oral glucose tolerance testing at 12 weeks of age
revealed improved glucose tolerance and increased insulin
secretion in hGPR40 transgenic  KK mice compared with
nontransgenic  KK mice (Fig. 5B–E). We next examined
the insulin secretion in response to glucose in vitro using
islets from hGPR40 transgenic  KK and nontransgenic 
KK mice at 12 weeks of age. Although basal insulin
secretion from islets in response to a low glucose concen-
tration (3 mmol/l) was closely similar between hGPR40
transgenic  KK and nontransgenic  KK mice, insulin
secretion against high glucose stimulation (16 mmol/l) was
3.5-fold higher in hGPR40 transgenic  KK islets com-
pared with nontransgenic  KK islets (Fig. 5F). Stimula-
tion with 1 mmol/l palmitate produced more enhanced
insulin secretion in islets of hGPR40 transgenic  KK mice
than in islets of nontransgenic  KK mice at 11 mmol/l
glucose (Fig. 5G).
Gene expression of factors regulating insulin secre-
tion in islets isolated from hGPR40 transgenic mice.
To investigate the molecular mechanisms for enhanced
insulin secretion in response to high-glucose stimulation in
hGPR40 transgenic mice in vitro (Figs. 3C and D and 5F)
and in vivo (Figs. 2, 4, and 5), gene expression levels of
factors regulating insulin secretion were compared be-
tween islets from hGPR40 transgenic (47M) and nontrans-
genic mice after high-fat diet feeding for 9 weeks. The gene
expression levels of insulin II, GLUT2, and glucokinase
were found to be almost the same between islets of
hGPR40 transgenic and nontransgenic mice (Fig. 6). We
also examined the gene expression levels of UCP2, which
negatively regulates insulin secretion in -cells (26–28),
and the expression level of UCP2 did not change between
hGPR40 transgenic and nontransgenic mice (Fig. 6).
DISCUSSION
In this study, we have shown that overexpression of the
hGPR40 gene using insulin II promoter resulted in im-
proved glucose tolerance with augmented insulin secre-
tion, and the phenotype of hGPR40 transgenic mice was
not altered by high-fat–diet feeding or by gene transfer
into a diabetic background. We found extremely high
expression in pancreatic islets in two independent lines,
but slight expression was detected in kidney in the 47M
line. Both 47M and 23F hGPR40 transgenic mice showed
the same phenotype, and therefore it is unlikely that the
expression in kidney may affect the phenotype of hGPR40
transgenic mice. The hGPR40 transgenic mice showed
slightly lower plasma glucose levels than nontransgenic
mice in the fasted state but not in the fed state. These
results might reﬂect the differential activation of GPR40
between the fasted and the fed state because natural
ligands of GPR40 were FFAs (8–10), and FFA levels were
signiﬁcantly increased after an overnight fast in mice. In
the fasted state, GPR40 may be more strongly activated
than in the fed state, resulting in enhanced insulin secre-
tion and reduced plasma glucose levels. In fact, fasting
FIG. 2. Continued.
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genic mice than in nontransgenic mice.
Isolated islets from hGPR40 transgenic mice signiﬁ-
cantly secreted insulin when stimulated with palmitate, a
natural ligand of GPR40, and glucose per se. Although we
do not have direct evidence for GPR40 protein expression
level, it was proposed that GPR40 activation by fatty acids
stimulated the Gq-PLC signaling pathway, involving acti-
vation of PLC and production of inositol 1,4,5-triphos-
phate, which leads to release of calcium from the
endoplasmic reticulum (11,14–16). Glucose and fatty acids
could also augment insulin secretion through pathways
involving protein kinase C (29,30). The mechanism of
enhanced glucose-stimulated insulin secretion observed in
hGPR40 transgenic mice islets remains unclear so far, so
further studies will be needed to clarify the precise
mechanism.
Steneberg et al. (18) reported that the GPR40 transgenic
mice driven by the IPF-1/PDX-1 promoter had impaired
-cell function, hypoinsulinemia, and glucose intolerance,
suggesting the involvement of GPR40 in FFA-induced
toxicity in -cells. In contrast, our hGPR40 transgenic
mice did not develop diabetes, even after high-fat–diet
feeding for 8–12 weeks. The reason for the discrepancy
remains unknown. Although we may need further exami-
nation, the possible explanations are below. First is the
different promoters used for the production of transgenic
mice. The temporal pattern of expression of IPF-1/PDX-1
during development was different from that of insulin II
(31). Transgenes of GPR40 regulated by the IPF-1/PDX-1
promoter might be expressed in pancreatic progenitors in
the early embryonic stage, and these expression patterns
might be inﬂuenced to the phenotype. Second, it may be
caused by the difference in genetic background of each
transgenic mouse. Third, the difference in GPR40 gene
levels between our transgenic mice and Steneberg’s mice
might be a factor. In addition, our preliminary results
showed that the hGPR40 transgenic mice maintained
improved glucose tolerance with increased insulin secre-
tion when fed a high-fat diet for a long period (50
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FIG. 3. Islet structure and -cell function of hGPR40 transgenic mice and nontransgenic mice. A: Islet morphology of hGPR40 transgenic (47M
and 23F) and nontransgenic mice at 16 weeks of age. The sections were stained with anti-insulin, -glucagon, -GLUT2, and -proinsulin antibodies,
respectively. B: -Cell area was measured as the stained area for anti-insulin antibody. C and D: Glucose-stimulated insulin secretion in isolated
islets from hGPR40 transgenic and nontransgenic mice. E: Palmitate-stimulated insulin secretion in isolated islets from hGRP40 transgenic (47M)
mice and nontransgenic mice. Islets were isolated at 9 weeks from hGPR40 transgenic and nontransgenic mice fed regular diet. Five islets with
similar sizes from each group (four batches in each group) were used. All values are the means  SE. **P < 0.01, *P < 0.05 vs. nontransgenic mice
by Student’s t test. NonTg, nontransgenic; Tg, transgenic. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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parameters, including plasma insulin levels (data not
shown). Therefore, our results suggest that activation of
GPR40 function might not cause lipotoxicity. Latour et al.
(19) and Tan et al. (20) demonstrated that islets from
GPR40 knockout mice were as sensitive to fatty acid
inhibition of insulin secretion on prolonged exposure as
islets from wild-type animals, and they concluded that
GPR40 does not play a role in the mechanisms by which
fatty acids chronically impair insulin secretion. Moreover,
Kebede et al. (32) reported that GPR40 knockout mice
showed fasting hyperglycemia and were not protected
from high-fat–diet–induced insulin resistance. Although
further studies will be needed to clarify the relationship
between GPR40 and lipotoxicity, these observations are
consistent with our ﬁndings. Furthermore, small-molecule
agonists of GPR40 have been reported (20–22), and GPR40
agonists could enhance glucose-stimulated insulin secre-
tion and improve glucose tolerance both acutely and
chronically. Results from these reports indicate that acti-
FIG. 4. Effects of high-fat–diet feeding on glucose homeostasis in hGPR40 transgenic mice. The hGPR40 transgenic (47M) and nontransgenic mice
were fed on 60 kcal% fat diet from 8 weeks of age. Oral glucose tolerance testing was used for hGPR40 transgenic mice and nontransgenic mice.
Glucose was administered orally at 1 g/kg body wt. A and B: Plasma glucose (A) and plasma insulin (B) at 17 weeks of age, respectively. Data in
panel C represent the AUC0–120 minof plasma glucose shown in panel A, and data in panel D represent the AUC0–30 min of plasma insulin shown in
panel B. E: Insulin tolerance test for nontransgenic and hGPR40 transgenic mice. Insulin was injected intraperitoneally at 0.5 units/kg. Plasma
glucose of high-fat–diet–fed mice at 20 weeks of age. F: Epididymal adipose tissue weight at 20 weeks of age. All values are the means  SE (n 
10). **P < 0.01 vs. nontransgenic mice by Student’s t test. NonTg, nontransgenic; Tg, transgenic.
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DIABETES, VOL. 58, MAY 2009 1073FIG. 5. Improved glucose tolerance in hGPR40 transgenic mice harboring diabetic KK background on regular diet. A: Human and mouse GPR40
mRNA levels in islets from hGPR40 transgenic  KK and nontransgenic  KK mice (n  3) by quantitative real-time PCR analyses. mRNA levels
of actin were used as an internal control. B–E: Oral glucose tolerance test for hGPR40 transgenic mice and nontransgenic mice harboring hybrid
background. Glucose was administered orally at 2 g/kg body wt. B and C: Plasma glucose (B) and plasma insulin (C) at 12 weeks of age on regular
diet. Data in panel D represent the AUC0–120 min of plasma glucose shown in panel B, and data in panel E represent the AUC0–30 min of plasma
insulin shown in panel C. F and G: Glucose- and palmitate-stimulated insulin secretion in isolated islets from hGPR40 transgenic  KK and
nontransgenic  KK mice. Islets were isolated from regular diet–fed mice at 12 weeks. Five islets with similar sizes from each group (four batches
in each group) were used. All values are means  SE (n  8–10). **P < 0.01, *P < 0.05 vs. nontransgenic mice by Student’s t test. NonTg,
nontransgenic; Tg, transgenic.
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type 2 diabetes without lipotoxicity, and the phenotypes of
our hGPR40 transgenic mice strongly support this
conclusion.
Obesity commonly induces insulin resistance and
causes an increase in the requirement of insulin secretion
from the pancreas, and the enhancement of this phenom-
enon further exacerbates obesity and insulin resistance.
The molecular mechanism of this phenomenon is unclear,
but it may be related to increased production and secre-
tion of nonesteriﬁed fatty acids and metabolically harmful
adipokines by insulin-resistant adipocytes during obesity
(33–35). In our results, hGPR40 transgenic mice fed a
high-fat diet did not show signiﬁcant differences in body
weight, adipose tissue weight, and plasma insulin level.
Moreover, when insulin resistance was reinforced by
crossing with KK background–harboring mice, hGPR40
transgenic  KK mice did not show signiﬁcant differences
in body weight and plasma insulin level from nontrans-
genic  KK mice. Therefore, activation of GPR40 may not
cause sustained hyperinsulinemia but may enhance glu-
cose-stimulated insulin secretion essentially in the pran-
dial period.
The M3 muscarinic acetylcholine receptor subtype cou-
ples with Gq in pancreatic -cells (36–37). It has been
reported that overexpressed M3 muscarinic receptors in
pancreatic -cells showed almost the same phenotype as
the hGPR40 transgenic mice (38), and the potentiation of
Gq signaling in pancreatic -cells may lead to the main-
tenance of proper insulin release and glucose homeostasis
in vivo.
In conclusion, our results demonstrate that GPR40 may
play an important role in the regulation of glucose-stimu-
lated insulin secretion and glucose homeostasis. Our ob-
servation indicates that GPR40 might be concerned with
an overt increase in insulin secretion in the presence of
elevated glucose, such as during the postprandial period,
and that speciﬁc agonists may be useful as novel insulin
secretagogues with low risk of hypoglycemia.
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